Home/Filings/4/0001209191-20-040341
4//SEC Filing

Meyer Ernie 4

Accession 0001209191-20-040341

CIK 0001269021other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 4:33 PM ET

Size

25.6 KB

Accession

0001209191-20-040341

Insider Transaction Report

Form 4
Period: 2020-07-02
Meyer Ernie
EVP and CHRO
Transactions
  • Award

    Common Stock

    2020-06-18$8.36/sh+789$6,596789 total
  • Disposition to Issuer

    Performance Stock Units

    2020-07-0248,7500 total
    Common Stock (48,750 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-07-02162,5000 total
    Common Stock (162,500 underlying)
  • Disposition to Issuer

    Common Stock

    2020-07-02$18.00/sh9,541$171,7380 total
  • Disposition to Issuer

    Performance Stock Units

    2020-07-0224,3750 total
    Common Stock (24,375 underlying)
  • Award

    Common Stock

    2020-02-28$8.59/sh+353$3,0329,541 total
  • Disposition to Issuer

    Common Stock

    2020-07-02$18.00/sh789$14,2020 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-07-02$5.21/sh65,000$338,6500 total
    Exercise: $12.79Exp: 2030-01-30Common Stock (65,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-07-0232,5000 total
    Exercise: $12.79Exp: 2030-01-30Common Stock (32,500 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2020-07-0248,7500 total
    Common Stock (48,750 underlying)
Footnotes (9)
  • [F1]The acquisition of 353 shares by the Reporting Person on February 28, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F2]Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
  • [F3]The acquisition of 789 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F4]Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").
  • [F5]In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.
  • [F6]At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
  • [F7]At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
  • [F8]In connection with the Merger, these options were accelerated and canceled without payment.
  • [F9]At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Issuer

PORTOLA PHARMACEUTICALS INC

CIK 0001269021

Entity typeother

Related Parties

1
  • filerCIK 0001750864

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:33 PM ET
Size
25.6 KB